Canadian Vascular Quality Initiative (CVQI)

September 24, 2021
9:00 am – 11:30 am (ET)
Remote
Meeting Attendance Credit

Before we get started, please sign in.

1. Click “Participants” in the box at the top or bottom of your screen.
2. If your full name is not listed, hover next to your name and you’ll see “rename”.
3. Click and sign in.

If you can’t sign in, please email Leka Johnson at ljohnson@svspso.org and let her know the identifier you were signed in under (ex –LM7832 or your phone number).

**SPECIAL NOTE:  We do give credit to residents/fellows that don’t have a PATHWAYS user account !!!

Sign in with your Full name, MD, Name of Institution
## Agenda - Canadian VQI September 24, 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>CE Credit</th>
</tr>
</thead>
<tbody>
<tr>
<td>9am</td>
<td>Welcome</td>
<td>No</td>
</tr>
<tr>
<td>9:05am</td>
<td>Regional Data Review – Dr. Graham Roche-Nagle, CVQI Medical Director</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Dr. Yaasin Abdulrehman, CVQI Associate Medical Director</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Use the VQI regional reports to establish quality improvement goals for the vascular patients (outcomes) and for their center (process).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Interpret and compare each centers’ VQI results to regional and national benchmarked data.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Learn, through group discussion the VQI regional results to improve the quality of vascular health care by monitoring measurable performance indicators, SVS PSO evidence-based research, and outcomes.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify high performing regional vascular centers to discuss variations in care and clinical practice patterns to improve outcomes and prompt quality improvement recommendations for vascular care patients. Sharing of best practices/pathways of care.</td>
<td></td>
</tr>
<tr>
<td>10:05am</td>
<td>Regional QI Proposal – Dr. Graham Roche-Nagle, CVQI Medical Director</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Dr. Yaasin Abdulrehman, CVQI Associate Medical Director</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Use the VQI regional reports to establish quality improvement goals for the vascular patients (outcomes) and for their center (process).</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Interpret and compare each centers’ VQI results to regional and national benchmarked data.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Learn, through group discussion the VQI regional results to improve the quality of vascular health care by monitoring measurable performance indicators, SVS PSO evidence-based research, and outcomes.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify high performing regional vascular centers to discuss variations in care and clinical practice patterns to improve outcomes and prompt quality improvement recommendations for vascular care patients. Sharing of best practices/pathways of care.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Topic</td>
<td>CE Credit</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>10:35am</td>
<td>National VQI Update – Betsy Wymer, DNP, RV, RN-BC, PSO Quality Director</td>
<td>Yes</td>
</tr>
<tr>
<td></td>
<td>Learning Objectives:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Use the VQI regional reports to establish quality improvement goals for the vascular patients (outcomes) and for their center (process)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify high performing regional vascular centers to discuss variations in care and clinical practice patterns to improve outcomes and prompt quality improvement recommendations for vascular care patients. Sharing of best practices/pathways of care</td>
<td></td>
</tr>
<tr>
<td>11:05am</td>
<td>AQC Update – Mary MacDonald, MD</td>
<td>No</td>
</tr>
<tr>
<td>11:10am</td>
<td>VQC Update – Graham Roche-Nagle, MD</td>
<td>No</td>
</tr>
<tr>
<td>11:15am</td>
<td>RAC Update – Graham Roche-Nagle, MD</td>
<td>No</td>
</tr>
<tr>
<td>11:20am</td>
<td>Governing Council Update – Graham Roche-Nagle, MD</td>
<td>No</td>
</tr>
<tr>
<td>11:25am</td>
<td>Case Presentations</td>
<td>No</td>
</tr>
<tr>
<td></td>
<td>VQI Quality Initiatives at NS Health - Alexa Grant-Gorveatt</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thresholds for AAA Repair in Canada and United States - Ben Li</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sex Differences in Outcomes Following Ruptured AAA Repair - Ben Li</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Effect of Vertebral Compression Fractures on Aortic Neck Angulation after EVAR - Omid Shearkhani</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Endovascular Community Response to Mortality Data in Use of Paclitaxel Devices for PVD- Blair Warren</td>
<td></td>
</tr>
<tr>
<td>11:30am</td>
<td>Open Discussion/Next Meeting/Meeting Evaluation</td>
<td>No</td>
</tr>
</tbody>
</table>
No presenter has a disclosure or conflict of interest to report.
Welcome and Introductions

CHUM
CISSSO Outaouais
Covenant Health-Grey Nuns Hospital
Halifax Infirmary Robie Street
Entrance - QEII
Peter Lougheed Centre
Sunnybrook Health Sciences Centre
Thunder Bay Regional Health
Science Center
Toronto General Hospital

Guest: Hamilton Health Sciences
Fall Regional Reports

Dr. Graham Roche-Nagle
Dr. Yaasin Abdulrehman

VQI Regional Quality Report

Fall 2021

This report is patient safety work product generated within the SVS PSO, LLC, and is considered privileged and confidential.

About the Report

The VQI Regional Quality Report is produced semiannually to provide centers and regions targeted, comparative results and benchmarks for a variety of procedures, process measures, and postoperative outcomes. The report is organized into separate reports that can be quickly accessed by clicking on the report names in the table of contents on the left.

For drill-down and data feedback on your center’s cases, click on “VQI Case Appendix” in the table of contents on the left.
Important Notes

- All results are based on data entered into the VQI as of June 30, 2021. Any subsequent changes or updates to data after that date will not be reflected in this report.

- Procedure timeframes and inclusion/exclusion criteria are given at the top of each report. Cases are also excluded if outcomes are missing or not enough data was entered to determine whether the case met inclusion/exclusion criteria.

- Regions must have at least 3 centers with included cases for regional results to be displayed in tables and line charts.

- Regions must have at least 3 centers with at least 10 included cases per center for regional results to be displayed in bar charts. It is therefore possible for a region’s results to be displayed in tables and line charts, but not in bar charts.

- For risk-adjusted reports, regions must have at least 3 centers with at least 10 complete cases per center for regional results to be displayed in bar charts. It is therefore possible for a region’s results to be displayed in tables and line charts, but not in bar charts.

- In all graphics, "**" indicates a p-value <.05.
**Fall 2021 Important Report Updates:**

- **Display of 10\textsuperscript{th}/90\textsuperscript{th} percentiles**
  The 10\textsuperscript{th} and 90\textsuperscript{th} percentiles for center rates in your region and across VQI are now provided in the dashboard. These percentiles give users a broader picture of the distribution of center-level rates and may provide opportunities for more targeted monitoring of outcomes.

- **Region Volume Appendix**
  A new Region Volume Appendix is now provided as part of your regional slide deck. This new appendix provides your region’s case volumes for each report. In addition, the number of centers contributing data to each report is given.

- **Long-Term Follow-up**
  Mandatory fields for long-term follow-up were released in PATHWAYS in September 2018 to provide a more accurate assessment of long-term follow-up rates. While no changes have been made to the long-term follow-up report, centers and regions should note that long-term follow-up rates for more recent procedure timeframes (e.g., July 2018-June 2019) are reflective of these mandatory fields.
Fall 2021 Important Report Updates:

- **TCAR**
  Changed inclusion/exclusion criteria – Procedures with an approach other than Carotid Percutaneous or Carotid Open are now excluded from both ASYMP and SYMP reports.

- **OAAA**
  Low procedure volumes for OAAA have historically resulted in only a small number of regions having access to their regional OAAA results. To remedy this situation and provide more meaningful feedback to centers and regions alike, the procedure timeframe for assessment in OAAA reports has been extended from 1 year to 4 years. Accordingly, all assessments in these reports are now based on 4 years of data. Centers and regions should note the following additions to the line charts associated with these reports:
    - For center-specific reports, the center’s aggregate 4-year rate is now displayed with a dashed yellow line.
    - For regional slide decks, the region’s aggregate 4-year rate is now displayed with a dashed light-blue line.
Dashboard

The dashboard provides a high-level summarization of your center’s results for each of 25 reports, and gives both regional and VQI-wide benchmarks for comparison. The “Your Center” column gives the percentage of your center’s cases with the noted outcome. Numbers in parentheses give the number of cases with the outcome and the total number of cases meeting the inclusion criteria for that report. The “Your Region” and “VQI Overall” columns give the aggregate percentage of cases with the noted outcome, as well as the 10th, 25th, 50th (median), 75th, and 90th percentiles for centers in your region and VQI, respectively ([10th|25th|50th|75th|90th]). Your center’s results are highlighted blue if your center is in the “top” 25th percentile for VQI Overall, and coral if your center is in the “bottom” 25th percentile for VQI Overall.

For details on a particular report, click on the report name in the table of contents on the left.

Legend: Blue = “Top” 25th percentile Coral = “Bottom” 25th percentile

*Note that procedure volume results are not highlighted.*
18 Regional Quality Groups
Today’s Focus for CVQI

CVQI is:
- Doing Great
- Growing
- Unique
- Not Homogenous
- Has Room for Improvement
CVQI is doing **Great**

- LTFU
- LOS after EVAR
- EVAR sac diameter reporting
CVQI is doing **Growing**

- Centers on future slide
- Guest today from Hamilton Health Services
  - Welcome Tara Andrinopoulos, Research Coordinator
CVQI is Unique

- We do some things better
- We do some things different
  - OAAA
Today’s Focus for CVQI

CVQI is not homogenous
- We have outliers either end of the spectrum
- We can learn from each other
  - Consider self-disclosing during this meeting
  - Best practices (what works/what didn’t)
- Recommend unblinding data
  - Process measures only (EVAR sac diameter, LTFU)
  - Must be voted on (Leka to send out vote)
Today’s Focus for CVQI

CVQI can improve

- Stroke or death after CEA Symptomatic
- LOS after CEA Symptomatic
Dashboard

The dashboard provides a high-level summarization of your center's results for each of 25 reports, and gives both regional and VQI-wide benchmarks for comparison. The "Your Center" column gives the percentage of your center's cases with the noted outcome. Numbers in parentheses give the number of cases with the outcome and the total number of cases meeting the inclusion criteria for that report. The "Your Region" and "VQI Overall" columns give the aggregate percentage of cases with the noted outcome, as well as the 10th, 25th, 50th (median), 75th, and 90th percentiles for centers in your region and VQI, respectively. Your center's results are highlighted blue if your center is in the "top" 25th percentile for VQI Overall, and coral if your center is in the "bottom" 25th percentile for VQI Overall.

For details on a particular report, click on the report name in the table of contents on the left.

### Procedure Group

<table>
<thead>
<tr>
<th>Procedure Group</th>
<th>Outcome</th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Procedure Volume</td>
<td>[54</td>
<td>136</td>
<td>378</td>
</tr>
<tr>
<td>Multiple</td>
<td>Procedure Volume, All Years</td>
<td>[226</td>
<td>468</td>
<td>601</td>
</tr>
<tr>
<td>TFEM CAS ASYMPC</td>
<td>Stroke/Death</td>
<td>NA (&lt;3 centers)</td>
<td>1.8% [0</td>
<td>0</td>
</tr>
<tr>
<td>TFEM CAS SYMPP</td>
<td>Stroke/Death</td>
<td>NA (&lt;3 centers)</td>
<td>1.4% [0</td>
<td>0</td>
</tr>
<tr>
<td>CEA ASYMPP</td>
<td>Stroke/Death</td>
<td>1.2% [0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>CEA SYMPP</td>
<td>Postop LOS&gt;1 Day</td>
<td>40.2% [28</td>
<td>54</td>
<td>60</td>
</tr>
<tr>
<td>EVAR</td>
<td>Postop LOS&gt;2 Days</td>
<td>11.2% [4</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>TEVAR</td>
<td>Sac Diameter Reporting</td>
<td>86.7% [35</td>
<td>73</td>
<td>83</td>
</tr>
<tr>
<td>OAAA</td>
<td>Sac Diameter Reporting</td>
<td>NA (&lt;3 centers)</td>
<td>55.7% [0</td>
<td>20</td>
</tr>
<tr>
<td>PVI CLAUD</td>
<td>ABI/Toe Pressure</td>
<td>85.6% [74</td>
<td>79</td>
<td>84</td>
</tr>
<tr>
<td>INFRA CLTI</td>
<td>Major Complications</td>
<td>98.6% [95</td>
<td>98</td>
<td>99</td>
</tr>
<tr>
<td>SUPRA CLTI</td>
<td>Major Complications</td>
<td>6.4% [1</td>
<td>3</td>
<td>7</td>
</tr>
<tr>
<td>LEARM</td>
<td>Postop Complications</td>
<td>NA (&lt;3 centers)</td>
<td>10.8% [0</td>
<td>0</td>
</tr>
<tr>
<td>HDA</td>
<td>Primary AVF vs. Graft</td>
<td>94.8% [84</td>
<td>87</td>
<td>94</td>
</tr>
<tr>
<td>IVCF</td>
<td>Filter Retrieval Reporting</td>
<td>NA (&lt;3 centers)</td>
<td>56% [13</td>
<td>36</td>
</tr>
</tbody>
</table>
# Region Volume Appendix

## Fall 2021

### About the Appendix

The Region Volume Appendix provides your region’s case volumes for each report. In addition, the number of centers with cases contributing to each report is given. Note that columns referencing complete cases are appropriately left blank for non-risk-adjusted reports.

<table>
<thead>
<tr>
<th>Report</th>
<th>Included Cases</th>
<th>Centers with Included Cases</th>
<th>Centers with at least 10 Included Cases</th>
<th>Complete Cases</th>
<th>Centers with Complete Cases</th>
<th>Centers with at least 10 Complete Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-Term Follow-up</td>
<td>1559</td>
<td>5</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discharge Medications</td>
<td>1729</td>
<td>7</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TFEM CAS ASYMP: Stroke/Death</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TFEM CAS SYMP: Stroke/Death</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TCAR ASYMP: Stroke/Death</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>TCAR SYMP: Stroke/Death</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>CEA ASYMP: Stroke/Death</td>
<td>82</td>
<td>5</td>
<td>2</td>
<td>69</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>CEA ASYMP: Postop LOS&gt;1 Day</td>
<td>82</td>
<td>5</td>
<td>2</td>
<td>69</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>CEA SYMP: Stroke/Death</td>
<td>112</td>
<td>5</td>
<td>3</td>
<td>102</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>CEA SYMP: Postop LOS&gt;1 Day</td>
<td>112</td>
<td>5</td>
<td>3</td>
<td>102</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>EVAR: Postop LOS&gt;2 Days</td>
<td>232</td>
<td>7</td>
<td>6</td>
<td>212</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>EVAR: Sac Diameter Reporting</td>
<td>188</td>
<td>5</td>
<td>4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVAR: SVS Sac Sizr Guideline</td>
<td>222</td>
<td>7</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEVAR: Sac Diameter Reporting</td>
<td>36</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OAAA: In-Hospital Mortality</td>
<td>414</td>
<td>5</td>
<td>4</td>
<td>384</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>OAAA: SVS Cell-Saver Guideline</td>
<td>431</td>
<td>5</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OAAA: SVS Iliac Inflow Guideline</td>
<td>440</td>
<td>5</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PVI CLAUDI: ABI/Toe Pressure</td>
<td>224</td>
<td>5</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INFRA CLTI: Major Complications</td>
<td>211</td>
<td>5</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SUPRA CLTI: Major Complications</td>
<td>78</td>
<td>5</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LEAMP: Postop Complications</td>
<td>88</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDA: Primary AVF vs. Graft</td>
<td>153</td>
<td>3</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IVCF: Filter Retrieval Reporting</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Procedure Volume

Procedures performed between July 1, 2020 and June 30, 2021

Number of cases entered into the VQI, by registry and overall

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Your Center (N)</th>
<th>Your Region (N)</th>
<th>VQI Overall (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAS (TFEM CAS &amp; TCAR)</td>
<td></td>
<td>NA (&lt;3 centers)</td>
<td>13121</td>
</tr>
<tr>
<td>CEA</td>
<td></td>
<td>228</td>
<td>17107</td>
</tr>
<tr>
<td>EVAR</td>
<td></td>
<td>242</td>
<td>7240</td>
</tr>
<tr>
<td>HDA</td>
<td></td>
<td>172</td>
<td>6639</td>
</tr>
<tr>
<td>INFRA</td>
<td></td>
<td>249</td>
<td>7065</td>
</tr>
<tr>
<td>IVCF</td>
<td></td>
<td>NA (&lt;3 centers)</td>
<td>1525</td>
</tr>
<tr>
<td>LEAMP</td>
<td></td>
<td>NA (&lt;3 centers)</td>
<td>3077</td>
</tr>
<tr>
<td>OAAA</td>
<td></td>
<td>123</td>
<td>1305</td>
</tr>
<tr>
<td>PVI</td>
<td></td>
<td>795</td>
<td>41369</td>
</tr>
<tr>
<td>SUPRA</td>
<td></td>
<td>109</td>
<td>1870</td>
</tr>
<tr>
<td>TEVAR</td>
<td></td>
<td>52</td>
<td>2831</td>
</tr>
<tr>
<td>Varicose Veins</td>
<td></td>
<td>NA (&lt;3 centers)</td>
<td>6196</td>
</tr>
<tr>
<td>Overall (July 2020-June 2021)</td>
<td>2058</td>
<td></td>
<td>109345</td>
</tr>
<tr>
<td>Overall (July 2019-June 2020)</td>
<td>2021</td>
<td></td>
<td>112761</td>
</tr>
</tbody>
</table>
Procedure Volume by Center in Your Region (July 2020–June 2021)

- Other centers in your region
- Your center

Centers (centers with <10 cases not shown)

Procedure Volume Across VQI (July 2020–June 2021)

Regions (regions with <3 centers with at least 10 cases not shown)

"Others" indicates centers that do not belong to a regional group.
# Procedure Volume, All Years

Includes all procedures with procedure date through June 30, 2021

Number of cases entered into the VQI, by registry and overall

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Your Center (N)</th>
<th>Your Region (N)</th>
<th>VQI Overall (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAS (TFEM CAS &amp; TCAR)</td>
<td>NA (&lt;3 centers)</td>
<td>1061</td>
<td>57614</td>
</tr>
<tr>
<td>CEA</td>
<td>1471</td>
<td>158265</td>
<td></td>
</tr>
<tr>
<td>EVAR</td>
<td>934</td>
<td>63655</td>
<td></td>
</tr>
<tr>
<td>HDA</td>
<td>1357</td>
<td>62972</td>
<td></td>
</tr>
<tr>
<td>INFRA</td>
<td>NA (&lt;3 centers)</td>
<td>66699</td>
<td></td>
</tr>
<tr>
<td>IVCF</td>
<td>15864</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LEAMP</td>
<td>NA (&lt;3 centers)</td>
<td>21477</td>
<td></td>
</tr>
<tr>
<td>OAAA</td>
<td>733</td>
<td>14897</td>
<td></td>
</tr>
<tr>
<td>PVI</td>
<td>3856</td>
<td>274908</td>
<td></td>
</tr>
<tr>
<td>SUPRA</td>
<td>684</td>
<td>21514</td>
<td></td>
</tr>
<tr>
<td>TEVAR</td>
<td>362</td>
<td>20751</td>
<td></td>
</tr>
<tr>
<td>Varicose Veins</td>
<td>NA (&lt;3 centers)</td>
<td>46683</td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>10642</td>
<td>825299</td>
<td></td>
</tr>
</tbody>
</table>
Procedure Volume by Center in Your Region (Through June 2021)

- Other centers in your region
- Your center

Centers (centers with <10 cases not shown)

Procedure Volume Across VQI (Through June 2021)

Regions (regions with <3 centers with at least 10 cases not shown)

*Others* indicates centers that do not belong to a regional group.
Physician Specialties

Physician Specialties Across VQI (as of July 31, 2021, N=6074 Physicians)
Physician Specialties Across Your Region (as of July 31, 2021, N=54 Physicians)
Long-Term Follow-up

Procedures performed between July 1, 2018 and June 30, 2019

Includes CAS (TFEM CAS and TCAR), CEA, EVAR, HDA, INFRA, IVCF, LEAMP, OAAA, PVI, SUPRA, and TEVAR procedures only. Excludes cases not eligible for long-term follow-up.

The table below gives the number of procedures meeting the inclusion criteria, and the percentage of those procedures with follow-up recorded between 9 and 21 months post-procedure.

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAS</td>
<td>NA (&lt;3 centers)</td>
<td>157 (94%)</td>
<td>9602 (62%)</td>
</tr>
<tr>
<td>CEA</td>
<td>207 (86%)</td>
<td>8030 (64%)</td>
<td>18987 (70%)</td>
</tr>
<tr>
<td>EVAR</td>
<td>218 (90%)</td>
<td>7148 (72%)</td>
<td>7432 (69%)</td>
</tr>
<tr>
<td>HDA</td>
<td>NA (&lt;3 centers)</td>
<td>3272 (66%)</td>
<td>8030 (64%)</td>
</tr>
<tr>
<td>INFRA</td>
<td>97 (94%)</td>
<td>1286 (74%)</td>
<td>7148 (72%)</td>
</tr>
<tr>
<td>IVCF</td>
<td>NA (&lt;3 centers)</td>
<td>1922 (76%)</td>
<td>8030 (64%)</td>
</tr>
<tr>
<td>LEAMP</td>
<td>NA (&lt;3 centers)</td>
<td>3272 (66%)</td>
<td>8030 (64%)</td>
</tr>
<tr>
<td>OAAA</td>
<td>95 (88%)</td>
<td>1559 (90%)</td>
<td>2286 (70%)</td>
</tr>
<tr>
<td>PVI</td>
<td>525 (86%)</td>
<td>2852 (65%)</td>
<td>36370 (67%)</td>
</tr>
<tr>
<td>SUPRA</td>
<td>95 (88%)</td>
<td>1540 (86%)</td>
<td>36370 (67%)</td>
</tr>
<tr>
<td>TEVAR</td>
<td>NA (&lt;3 centers)</td>
<td>2852 (65%)</td>
<td>99187 (68%)</td>
</tr>
<tr>
<td>Overall (July 2018-June 2019)</td>
<td>90835 (73%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall (July 2017-June 2018)</td>
<td>90835 (73%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Long-Term Follow-Up by Year

- Your Center
- Your Region
- VQI Overall

July 2015-June 2016
July 2016-June 2017
July 2017-June 2018
July 2018-June 2019
## Discharge Medications

Procedures performed between July 1, 2020 and June 30, 2021

Includes CAS (TFEM CAS and TCAR), CEA, EVAR, INFRA, LEAMP, OAAA, PVI, SUPRA, and TEVAR procedures only. Antiplatelet is defined as ASA or P2Y12 inhibitor. Cases are excluded if (1) Discharge Statin = “No, for medical reason” OR (2) Both Discharge ASA = “No, for medical reason” AND Discharge P2Y12 inhibitor = “No, for medical reason” OR (3) An in-hospital death occurred.

The table below gives the number of procedures meeting the inclusion criteria, and the percentage of those procedures where patients received discharge medications.

<table>
<thead>
<tr>
<th></th>
<th>Number of Procedures at Your Center</th>
<th>Antiplatelet+Statin</th>
<th>Antiplatelet Only</th>
<th>Statin Only</th>
<th>Neither</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CEA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EVAR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INFRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LEAMP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OAAA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PVI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SUPRA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TEVAR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Your Center Overall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Your Region Overall</td>
<td>1729</td>
<td>82%</td>
<td>7%</td>
<td>8%</td>
<td>3%</td>
</tr>
<tr>
<td>VQI Overall</td>
<td>89002</td>
<td>86%</td>
<td>9%</td>
<td>3%</td>
<td>2%</td>
</tr>
</tbody>
</table>
Discharge Antiplatelet+Statin by Center in Your Region (July 2020–June 2021)

**Other centers in your region** | **Your center**
---|---
100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% | 0%

Centers (centers with <10 cases not shown)

***Indicates center’s rate differs significantly from the regional rate.***

Discharge Antiplatelet+Statin by Region Across VQI (July 2020–June 2021)

- New England
- Nor. Cal.
- Up. Midwest
- Midwest
- O. Lakes
- Mid-America
- Michigan
- Carolinas
- MidSouth
- Others
- YQL
- Pacific NW
- So. Cal.
- SoVQI
- Virginia
- Mid-Atlantic
- Canada
- Rocky Mtn.
- New York
- Southeast

Regions (regions with <3 centers with at least 10 cases not shown)

"Others" indicates centers that do not belong to a regional group.

***Indicates region’s rate differs significantly from the VQI rate."
**TFEM CAS ASYMP: Stroke/Death**

Procedures performed between July 1, 2020 and June 30, 2021

Includes asymptomatic admissions for Transfemoral Carotid Artery Stenting (TFEM CAS) only. Asymptomatic admissions are admissions where the patient had no ipsilateral or contralateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar TIA or stroke, prior ipsilateral CAS, CAS for intracranial treatment, or any procedure involving dissection, trauma, FMD, or “Other” lesion types. Procedures with an approach other than Femoral are also excluded.

The table below gives the number of TFEM CAS procedures (performed on asymptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of in-hospital stroke or death for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of TFEM CAS procedures meeting inclusion criteria</td>
<td>NA (&lt;3 centers)</td>
<td>1.8%</td>
<td>1751</td>
</tr>
<tr>
<td>Observed rate of stroke or death among procedures meeting inclusion criteria</td>
<td>1610</td>
<td>1.7%</td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>NA</td>
<td>1610</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among cases with complete data</td>
<td>NA</td>
<td>1610</td>
<td></td>
</tr>
<tr>
<td>Expected rate of stroke or death among cases with complete data</td>
<td>NA</td>
<td>1610</td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>NA</td>
<td>1610</td>
<td></td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Stroke or Death after TFEM CAS for Asymptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
Stroke or Death after TFEM CAS for Asymptomatic Admissions in Your Region (July 2020–June 2021)

Centers (centers with <10 complete cases not shown)

Rates shown are among complete cases. "***" indicates center's observed rate differs significantly from its expected rate.

Stroke or Death after TFEM CAS for Asymptomatic Admissions by Region Across VQI (July 2020–June 2021)

Regions (regions with <3 centers with at least 10 complete cases not shown)

Rates shown are among complete cases. "***" indicates region's observed rate differs significantly from its expected rate.
TFEM CAS SYMP: Stroke/Death

Procedures performed between July 1, 2020 and June 30, 2021

Includes symptomatic admissions for Transfemoral Carotid Artery Stenting (TFEM CAS) only. Symptomatic admissions are admissions where the patient had an ipsilateral or contralateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar TIA or stroke, prior ipsilateral CAS, CAS for intracranial treatment, or any procedure involving dissection, trauma, FMD, or “Other” lesion types. Procedures with an approach other than Femoral are also excluded.

The table below gives the number of TFEM CAS procedures (performed on symptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of in-hospital stroke or death for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of TFEM CAS procedures meeting inclusion criteria</td>
<td>NA (&lt;3 centers)</td>
<td>1717</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among procedures meeting inclusion criteria</td>
<td>5.9%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>1595</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among cases with complete data</td>
<td>6.1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expected rate of stroke or death among cases with complete data</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Stroke or Death after TFEM CAS for Symptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
Stroke or Death after TFEM CAS for Symptomatic Admissions in Your Region (July 2020–June 2021)

Centers (centers with <10 complete cases not shown)

Rates shown are among complete cases. **** Indicates center's observed rate differs significantly from its expected rate.

Stroke or Death after TFEM CAS for Symptomatic Admissions by Region Across VQI (July 2020–June 2021)

Regions (regions with <3 centers with at least 10 complete cases not shown)

Rates shown are among complete cases. **** Indicates region's observed rate differs significantly from its expected rate.
TCAR ASYMP: Stroke/Death

Procedures performed between July 1, 2020 and June 30, 2021

Includes asymptomatic admissions for TransCarotid Artery Revascularization (TCAR) only. Asymptomatic admissions are admissions where the patient had no ipsilateral or contralateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar TIA or stroke, prior ipsilateral CAS, CAS for intracranial treatment, or any procedure involving dissection, trauma, FMD, or “Other” lesion types. Procedures with an approach other than Carotid Percutaneous or Carotid Open are also excluded.

The table below gives the number of TCAR procedures (performed on asymptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of in-hospital stroke or death for those cases.

<table>
<thead>
<tr>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of TCAR procedures meeting inclusion criteria</td>
<td>NA (&lt;3 centers)</td>
<td>4432</td>
</tr>
<tr>
<td>Observed rate of stroke or death among procedures meeting inclusion criteria</td>
<td></td>
<td>1.4%</td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td></td>
<td>4239</td>
</tr>
<tr>
<td>Observed rate of stroke or death among cases with complete data</td>
<td></td>
<td>1.4%</td>
</tr>
<tr>
<td>Expected rate of stroke or death among cases with complete data</td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td></td>
<td>NA</td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Stroke or Death after TCAR for Asymptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
Stroke or Death after TCAR for Asymptomatic Admissions in Your Region (July 2020–June 2021)

Centers (centers with <10 complete cases not shown)

Rates shown are among complete cases. *** Indicates center’s observed rate differs significantly from its expected rate.

Stroke or Death after TCAR for Asymptomatic Admissions by Region Across VQI
(July 2020–June 2021)

Regions (regions with <3 centers with at least 10 complete cases not shown)

Rates shown are among complete cases. *** Indicates region’s observed rate differs significantly from its expected rate.
**TCAR SYMP: Stroke/Death**

Procedures performed between July 1, 2020 and June 30, 2021

Includes symptomatic admissions for TransCarotid Artery Revascularization (TCAR) only. Symptomatic admissions are admissions where the patient had an ipsilateral or contralateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar TIA or stroke, prior ipsilateral CAS, CAS for intracranial treatment, or any procedure involving dissection, trauma, FMD, or “Other” lesion types. Procedures with an approach other than Carotid Percutaneous or Carotid Open are also excluded.

The table below gives the number of TCAR procedures (performed on symptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of in-hospital stroke or death for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of TCAR procedures meeting inclusion criteria</td>
<td>NA (&lt;3 centers)</td>
<td>2253</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among procedures meeting inclusion criteria</td>
<td>2.4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>2164</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among cases with complete data</td>
<td>2.3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expected rate of stroke or death among cases with complete data</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Stroke or Death after TCAR for Symptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
Stroke or Death after TCAR for Symptomatic Admissions in Your Region (July 2020–June 2021)

- Other centers in your region
- Your center
- Observed
- Expected

Centers (centers with <10 complete cases not shown)
Ratios shown are among complete cases. *** Indicates center’s observed rate differs significantly from its expected rate.

Stroke or Death after TCAR for Symptomatic Admissions by Region Across VQI (July 2020–June 2021)

- Observed
- Expected

Regions (regions with <3 centers with at least 10 complete cases not shown)
Ratios shown are among complete cases. *** Indicates region’s observed rate differs significantly from its expected rate.
CEA ASYMP: Stroke/Death

Procedures performed between July 1, 2020 and June 30, 2021

Includes asymptomatic admissions for Carotid Endarterectomy (CEA) only. Asymptomatic admissions are admissions where the patient had no ipsilateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar or non-specific TIA or stroke, prior ipsilateral CEA or CAS, or any procedure with a concomitant CABG, proximal endovascular, distal endovascular, or “Other” arterial procedure.

The table below gives the number of CEA procedures (performed on asymptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of in-hospital stroke or death for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of CEA procedures meeting inclusion criteria</td>
<td>82</td>
<td>9795</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among procedures meeting inclusion criteria</td>
<td>1.2%</td>
<td>1%</td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>69</td>
<td>9313</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among cases with complete data</td>
<td>1.4%</td>
<td>1%</td>
<td></td>
</tr>
<tr>
<td>Expected rate of stroke or death among cases with complete data</td>
<td>1.6%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>1</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

**“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.**
Stroke or Death after CEA for Asymptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
Stroke or Death after CEA for Asymptomatic Admissions in Your Region (July 2020-June 2021)

Centers (centers with <10 complete cases not shown)

Rates shown are among complete cases. "**" Indicates center's observed rate differs significantly from its expected rate.

Stroke or Death after CEA for Asymptomatic Admissions by Region Across VQI (July 2020-June 2021)

Regions (regions with <3 centers with at least 10 complete cases not shown)

Rates shown are among complete cases. "**" Indicates region's observed rate differs significantly from its expected rate.
CEA ASYMP: Postop LOS>1 Day

Procedures performed between July 1, 2020 and June 30, 2021

Includes asymptomatic admissions for Carotid Endarterectomy (CEA) only. Asymptomatic admissions are admissions where the patient had no ipsilateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar or non-specific TIA or stroke, prior ipsilateral CEA or CAS, or any procedure with a concomitant CABG, proximal endovascular, distal endovascular, or “Other” arterial procedure. Procedures where in-hospital death occurred with postoperative LOS<=1 day are also excluded. Postoperative LOS is based on the midnight rule used for hospital billing.

The table below gives the number of CEA procedures (performed on asymptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of postoperative LOS>1 Day for those cases.

<table>
<thead>
<tr>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of CEA procedures meeting inclusion criteria</td>
<td>82</td>
<td>9798</td>
</tr>
<tr>
<td>Observed rate of LOS&gt;1 day among procedures meeting inclusion criteria</td>
<td>40.2%</td>
<td>22.1%</td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>69</td>
<td>9330</td>
</tr>
<tr>
<td>Observed rate of LOS&gt;1 day among cases with complete data</td>
<td>42%</td>
<td>22%</td>
</tr>
<tr>
<td>Expected rate of LOS&gt;1 day among cases with complete data</td>
<td>26.2%</td>
<td>NA</td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>0.01</td>
<td>NA</td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Postop LOS > 1 Day after CEA for Asymptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
CEA SYMP: Stroke/Death

Procedures performed between July 1, 2020 and June 30, 2021

Includes symptomatic admissions for Carotid Endarterectomy (CEA) only. Symptomatic admissions are admissions where the patient had an ipsilateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar or non-specific TIA or stroke, prior ipsilateral CEA or CAS, or any procedure with a concomitant CABG, proximal endovascular, distal endovascular, or “Other” arterial procedure.

The table below gives the number of CEA procedures (performed on symptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of in-hospital stroke or death for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of CEA procedures meeting inclusion criteria</td>
<td>112</td>
<td>4843</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among procedures meeting inclusion criteria</td>
<td>3.6%</td>
<td>2.1%</td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>102</td>
<td>4660</td>
<td></td>
</tr>
<tr>
<td>Observed rate of stroke or death among cases with complete data</td>
<td>3.9%</td>
<td>2.1%</td>
<td></td>
</tr>
<tr>
<td>Expected rate of stroke or death among cases with complete data</td>
<td>2.1%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>0.16</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Stroke or Death after CEA for Symptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
CEA SYMP: Postop LOS>1 Day

Procedures performed between July 1, 2020 and June 30, 2021

Includes symptomatic admissions for Carotid Endarterectomy (CEA) only. Symptomatic admissions are admissions where the patient had an ipsilateral retinal or cortical TIA or stroke within 180 days prior to surgery. Excludes any patient with prior vertebrobasilar or non-specific TIA or stroke, prior ipsilateral CEA or CAS, or any procedure with a concomitant CABG, proximal endovascular, distal endovascular, or “Other” arterial procedure. Procedures where in-hospital death occurred with postoperative LOS<=1 day are also excluded. Postoperative LOS is based on the midnight rule used for hospital billing.

The table below gives the number of CEA procedures (performed on symptomatic admissions) meeting the inclusion criteria, and the observed and expected rates of postoperative LOS>1 Day for those cases.

<table>
<thead>
<tr>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of CEA procedures meeting inclusion criteria</td>
<td>112</td>
<td>4844</td>
</tr>
<tr>
<td>Observed rate of LOS&gt;1 day among procedures meeting inclusion criteria</td>
<td>47.3%</td>
<td>40.8%</td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>102</td>
<td>4681</td>
</tr>
<tr>
<td>Observed rate of LOS&gt;1 day among cases with complete data</td>
<td>48%</td>
<td>40.9%</td>
</tr>
<tr>
<td>Expected rate of LOS&gt;1 day among cases with complete data</td>
<td>42.4%</td>
<td>NA</td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>0.27</td>
<td>NA</td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
Postop LOS>1 Day after CEA for Symptomatic Admissions by Year

Rates shown are observed rates among cases meeting inclusion criteria.
**Postop LOS>1 Day after CEA for Symptomatic Admissions in Your Region (July 2020-June 2021)**

- **Other centers in your region**: Other centers in your region
- **Your center**: Your center
- **Observed**: Observed
- **Expected**: Expected

**Centers (centers with <10 complete cases not shown)**

Rates shown are among complete cases. "***" indicates center's observed rate differs significantly from its expected rate.

**Postop LOS>1 Day after CEA for Symptomatic Admissions by Region Across VQI (July 2020-June 2021)**

- **Observed**: Observed
- **Expected**: Expected

**Regions (regions with <3 centers with at least 10 complete cases not shown)**

Rates shown are among complete cases. "***" indicates region's observed rate differs significantly from its expected rate.
**EVAR: Postop LOS>2 Days**

Procedures performed between July 1, 2020 and June 30, 2021

Includes Endovascular AAA Repair (EVAR) procedures only. Excludes any procedure with ruptured aneurysm. Procedures where in-hospital death occurred with postoperative LOS≤2 are also excluded. Postoperative LOS is based on the midnight rule used for hospital billing.

The table below gives the number of EVAR procedures meeting the inclusion criteria, and the observed and expected rates of postoperative LOS>2 Days for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of EVAR procedures meeting inclusion criteria</td>
<td>232</td>
<td></td>
<td>6745</td>
</tr>
<tr>
<td>Observed rate of LOS&gt;2 days among procedures meeting inclusion criteria</td>
<td>11.2%</td>
<td>15.8%</td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>212</td>
<td></td>
<td>6187</td>
</tr>
<tr>
<td>Observed rate of LOS&gt;2 days among cases with complete data</td>
<td>10.4%</td>
<td>15.7%</td>
<td></td>
</tr>
<tr>
<td>Expected rate of LOS&gt;2 days among cases with complete data</td>
<td>15.5%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>0.04</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors."
Postop LOS > 2 Days after EVAR by Year

Rates shown are observed rates among cases meeting inclusion criteria.
EVAR: Sac Diameter Reporting

Procedures performed between July 1, 2018 and June 30, 2019

Includes Endovascular AAA Repair (EVAR) procedures only. Excludes patients who were converted to open or died within 21 months of surgery.

The table below gives the number of EVAR procedures meeting the inclusion criteria, and the percentage of those procedures where a sac diameter was reported between 9 and 21 months post-procedure.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of EVAR procedures meeting inclusion criteria</td>
<td>188</td>
<td>6878</td>
<td></td>
</tr>
<tr>
<td>Percentage with sac diameter reported between 9 and 21 months post-procedure</td>
<td>86.7%</td>
<td>56.1%</td>
<td></td>
</tr>
</tbody>
</table>
EVAR Sac Diameter Reporting by Year

July 2015-June 2016
July 2016-June 2017
July 2017-June 2018
July 2018-June 2019

Your Center
Your Region
VQI Overall
EVAR Sac Diameter Reporting in Your Region (July 2018–June 2019)

Other centers in your region  Your center

100%  90%  80%  70%  60%  50%  40%  30%  20%  10%  0%

Centers (centers with <10 cases not shown)

**** Indicates center’s rate differs significantly from the regional rate.

EVAR Sac Diameter Reporting by Region Across VQI (July 2018–June 2019)

Regions (regions with <3 centers with at least 10 cases not shown)

**** Indicates region’s rate differs significantly from the VQI rate.
EVAR: SVS Sac Size Guideline

Procedures performed between July 1, 2020 and June 30, 2021

Includes Endovascular AAA Repair (EVAR) procedures only. Excludes any non-elective procedure. SVS sac size guideline is ≥5 cm for Women and ≥5.5 cm for men. If the patient has any iliac aneurysm, the guideline is considered met regardless of AAA diameter.

The table below gives the number of EVAR procedures meeting the inclusion criteria, and the percentage of those procedures meeting the SVS sac size guideline.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of EVAR procedures meeting inclusion criteria</td>
<td>222</td>
<td></td>
<td>6031</td>
</tr>
<tr>
<td>Percentage meeting SVS sac size guideline</td>
<td>80.2%</td>
<td></td>
<td>74.3%</td>
</tr>
</tbody>
</table>
EVAR Sac Size Guideline in Your Region (July 2020–June 2021)

Centers (centers with <10 cases not shown)

**** Indicates center’s rate differs significantly from the regional rate.

EVAR Sac Size Guideline by Region Across VQI
(July 2020–June 2021)

Regions (regions with <3 centers with at least 10 cases not shown)

*** Indicates region’s rate differs significantly from the VQI rate.
TEVAR: Sac Diameter Reporting

Procedures performed between July 1, 2018 and June 30, 2019

Includes Thoracic Endovascular Aortic Repair (TEVAR) procedures for aneurysm or aneurysm from dissection only. Excludes cases where no aortic device was implanted or patients who were converted to open or died within 21 months of surgery.

The table below gives the number of TEVAR procedures meeting the inclusion criteria, and the percentage of those procedures where a sac diameter was reported between 9 and 21 months post-procedure.

<table>
<thead>
<tr>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of TEVAR procedures meeting inclusion criteria</td>
<td>NA (&lt;3 centers)</td>
<td>1590</td>
</tr>
<tr>
<td>Percentage with sac diameter reported between 9 and 21 months post-procedure</td>
<td></td>
<td>55.7%</td>
</tr>
</tbody>
</table>
TEVAR Sac Diameter Reporting in Your Region (July 2018–June 2019)

Other centers in your region  Your center

Centers (centers with <10 cases not shown)

*** indicates center’s rate differs significantly from the regional rate.

TEVAR Sac Diameter Reporting by Region Across VQI (July 2018–June 2019)

Southeast  New England  Virg./Nass  Mid-Atlantic  VQI  Midwest  Rocky Mtns  Carolinas  SoVOnet  So.-Cal.  New York  Mid-America

Regions (regions with <3 centers with at least 10 cases not shown)

*** indicates region’s rate differs significantly from the VQI rate.
OAAA: In-Hospital Mortality

Procedures performed between July 1, 2017 and June 30, 2021
Includes Open AAA (OAAA) procedures only. Excludes any patient with a ruptured aneurysm.

The table below gives the number of OAAA procedures meeting the inclusion criteria, and the observed and expected rates of in-hospital death for those cases.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of OAAA procedures meeting inclusion criteria</td>
<td>414</td>
<td>4436</td>
<td></td>
</tr>
<tr>
<td>Observed rate of In-Hospital Mortality among procedures meeting inclusion criteria</td>
<td>4.8%</td>
<td>4.4%</td>
<td></td>
</tr>
<tr>
<td>Number of procedures with complete data*</td>
<td>384</td>
<td>4139</td>
<td></td>
</tr>
<tr>
<td>Observed rate of In-Hospital Mortality among cases with complete data</td>
<td>4.2%</td>
<td>4.2%</td>
<td></td>
</tr>
<tr>
<td>Expected rate of In-Hospital Mortality among cases with complete data</td>
<td>3.9%</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>P-value for comparison of observed and expected rates</td>
<td>0.79</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

*“Expected rate” is the rate estimated by a statistical model that accounts for patient characteristics, including age, gender, race, BMI, comorbidities, medication and stroke and vascular history. “Cases with complete data” include patients who have data on all of those factors.
In-Hospital Death after OAAA by Year

Rates shown are observed rates among cases meeting inclusion criteria.
In-Hospital Death after OAAA in Your Region (July 2017–June 2021)

Centers (centers with <10 complete cases not shown)
Rates shown are among complete cases. *** Indicates center's observed rate differs significantly from its expected rate.

In-Hospital Death after OAAA by Region Across VQI (July 2017–June 2021)
Rates shown are among complete cases. *** Indicates region’s observed rate differs significantly from its expected rate.
OAAA: SVS Cell-Saver Guideline

Procedures performed between July 1, 2017 and June 30, 2021
Includes Open AAA (OAAA) procedures only. Excludes any patient with EBL ≤500 ml. SVS cell-saver guideline is met if cell salvage or ultrafiltration device was used.

The table below gives the number of OAAA procedures meeting the inclusion criteria, and the percentage of those procedures meeting the SVS cell-saver guideline.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of OAAA procedures meeting inclusion criteria</td>
<td></td>
<td>431</td>
<td>4545</td>
</tr>
<tr>
<td>Percentage meeting SVS cell-saver guideline</td>
<td></td>
<td>85.6%</td>
<td>92.4%</td>
</tr>
</tbody>
</table>
OAAA Cell-Saver Guideline in Your Region (July 2017–June 2021)

Other centers in your region • Your center

Centers (centers with <10 cases not shown)

OAAA Cell-Saver Guideline by Region Across VQI (July 2017–June 2021)

Regions (regions with <3 centers with at least 10 cases not shown)

**” Indicates center’s rate differs significantly from the regional rate.

**” Indicates region’s rate differs significantly from the VQI rate.
# OAAA: SVS Iliac Inflow Guideline

Procedures performed between July 1, 2017 and June 30, 2021

Includes Open AAA (OAAA) procedures only. SVS iliac inflow guideline is met if preservation of flow was maintained to at least one internal iliac artery.

The table below gives the number of OAAA procedures meeting the inclusion criteria, and the percentage of those procedures meeting the SVS iliac inflow guideline.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of OAAA procedures meeting inclusion criteria</td>
<td>440</td>
<td>5087</td>
<td></td>
</tr>
<tr>
<td>Percentage meeting SVS iliac inflow guideline</td>
<td>98.6%</td>
<td>97.4%</td>
<td></td>
</tr>
</tbody>
</table>
OAAA Iliac Inflow Guideline in Your Region (July 2017-June 2021)

Centers (centers with <10 cases not shown)

**Indicates center’s rate differs significantly from the regional rate.**

OAAA Iliac Inflow Guideline by Region Across VQI (July 2017-June 2021)

Regions (regions with <3 centers with at least 10 cases not shown)

**Indicates region’s rate differs significantly from the VQI rate.**
PVI CLAUD: ABI/Toe Pressure

Procedures performed between July 1, 2020 and June 30, 2021

Includes Peripheral Vascular Intervention (PVI) procedures for mild, moderate, or severe claudication only. “ABI/Toe Pressure Assessment” indicates at least one ABI or toe pressure assessment was made prior to PVI for the side of the procedure, or on both sides for bilateral and aortic procedures.

The table below gives the number of PVI procedures meeting the inclusion criteria, and the percentage of those procedures in which an ABI or toe pressure was assessed prior to PVI.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of PVI procedures meeting inclusion criteria</td>
<td></td>
<td>224</td>
<td>13720</td>
</tr>
<tr>
<td>Percentage with ABI/toe pressure assessment</td>
<td></td>
<td>77.7%</td>
<td>75.4%</td>
</tr>
</tbody>
</table>
ABI/Toe Pressure Assessment before PVI for Claudication in Your Region (July 2020-June 2021)

Other centers in your region  Your center

Centers (centers with <10 cases not shown)

*** Indicates center’s rate differs significantly from the regional rate.

ABI/Toe Pressure Assessment before PVI for Claudication by Region Across VQI
(July 2020-June 2021)

Regions (regions with <3 centers with at least 10 cases not shown)

*** Indicates region’s rate differs significantly from the VQI rate.
INFRA CLTI: Major Complications

Procedures performed between July 1, 2020 and June 30, 2021
Includes Infracrural Bypass (INFRA) procedures for rest pain, tissue loss, or acute ischemia. Major complications are defined as in-hospital death, ipsilateral BK or AK amputation, or graft occlusion.

The table below gives the number of INFRA procedures meeting the inclusion criteria, and the percentage of those procedures that resulted in in-hospital death, ipsilateral BK or AK amputation, or graft occlusion.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of INFRA procedures meeting inclusion criteria</td>
<td></td>
<td>211</td>
<td>5410</td>
</tr>
<tr>
<td>Percentage with major complications</td>
<td></td>
<td>5.7%</td>
<td>4.8%</td>
</tr>
</tbody>
</table>
Major Complications after INFRA for CLTI by Year

- Your Center
- Your Region
- VQI Overall

<table>
<thead>
<tr>
<th>Year</th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>July 2017-June 2018</td>
<td>8%</td>
<td>6%</td>
<td>5%</td>
</tr>
<tr>
<td>July 2018-June 2019</td>
<td>7%</td>
<td>5%</td>
<td>4%</td>
</tr>
<tr>
<td>July 2019-June 2020</td>
<td>6%</td>
<td>4%</td>
<td>3%</td>
</tr>
<tr>
<td>July 2020-June 2021</td>
<td>5%</td>
<td>3%</td>
<td>2%</td>
</tr>
</tbody>
</table>
Major Complications after INFRA for CLTI in Your Region (July 2020–June 2021)

- Other centers in your region
- Your center

Centers (centers with <10 cases not shown)

**"** Indicates center's rate differs significantly from the regional rate.

Major Complications after INFRA for CLTI by Region Across VQI (July 2020–June 2021)

Regions (regions with <3 centers with at least 10 cases not shown)

**"** Indicates region's rate differs significantly from the VQI rate.
SUPRA CLTI: Major Complications

Procedures performed between July 1, 2020 and June 30, 2021
Includes Suprainguinal Bypass (SUPRA) procedures for rest pain, tissue loss, or acute ischemia. Major complications are defined as in-hospital death, ipsilateral BK or AK amputation, or graft occlusion.

The table below gives the number of SUPRA procedures meeting the inclusion criteria, and the percentage of those procedures that resulted in in-hospital death, ipsilateral BK or AK amputation, or graft occlusion.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of SUPRA procedures meeting inclusion criteria</td>
<td></td>
<td>78</td>
<td>1143</td>
</tr>
<tr>
<td>Percentage with major complications</td>
<td></td>
<td>6.4%</td>
<td>8%</td>
</tr>
</tbody>
</table>
Major Complications after SUPRA for CLTI in Your Region (July 2020–June 2021)

Centers (centers with <10 cases not shown)

*** Indicates center’s rate differs significantly from the regional rate.

Major Complications after SUPRA for CLTI by Region Across VQI (July 2020–June 2021)

Regions (regions with <3 centers with at least 10 cases not shown)

*** Indicates region’s rate differs significantly from the VQI rate.
LEAMP: Postop Complications

Procedures performed between July 1, 2020 and June 30, 2021
Includes Lower-Extremity Amputation (LEAMP) procedures only. Postoperative complications are defined as myocardial infarction, dysrhythmia, congestive heart failure, surgical site infection, renal complication, or respiratory complication.

The table below gives the number of LEAMP procedures meeting the inclusion criteria, and the percentage of those procedures that resulted in a postoperative complication.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of LEAMP procedures meeting inclusion criteria</td>
<td>NA (&lt;3 centers)</td>
<td>3071</td>
<td></td>
</tr>
<tr>
<td>Percentage with postoperative complications</td>
<td></td>
<td></td>
<td>10.6%</td>
</tr>
</tbody>
</table>
Postop Complications after LEAMP by Year

- July 2017-June 2018
- July 2018-June 2019
- July 2019-June 2020
- July 2020-June 2021

Graph showing postoperative complications for LEAMP procedures by year, comparing Your Center, Your Region, and VQI Overall.
Postop Complications after LEAMP in Your Region (July 2020-June 2021)

Centers (centers with <10 cases not shown)

*** Indicates center’s rate differs significantly from the regional rate.

Postop Complications after LEAMP by Region Across VQI (July 2020-June 2021)

Regions (regions with <3 centers with at least 10 cases not shown)

*** Indicates region’s rate differs significantly from the VQI rate.
HDA: Primary AVF vs. Graft

Procedures performed between July 1, 2020 and June 30, 2021

Includes Hemodialysis Access (HDA) procedures only. Excludes procedures where Access Type = Endo AVF or patients with a previous access procedure in the same arm.

The table below gives the number of HDA procedures meeting the inclusion criteria, and the percentage of those procedures that were primary AVF.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of HDA procedures meeting inclusion criteria</td>
<td>153</td>
<td>5342</td>
<td></td>
</tr>
<tr>
<td>Percentage with primary AVF</td>
<td>94.8%</td>
<td>81.8%</td>
<td></td>
</tr>
</tbody>
</table>
Primary AVF Access by Year


Your Center  Your Region  VQI Overall
Primary AVF Access in Your Region (July 2020-June 2021)

- Other centers in your region
- Your center

Centers (centers with <10 cases not shown)

**** Indicates center's rate differs significantly from the regional rate.

Primary AVF Access by Region Across VQI (July 2020-June 2021)

Regions (regions with <3 centers with at least 10 cases not shown)

**** Indicates region's rate differs significantly from the VQI rate.
IVCF: Filter Retrieval Reporting

Procedures performed between July 1, 2018 and June 30, 2019

Includes Inferior Vena Cava Filter (IVCF) procedures only. Excludes filters with permanent planned duration, patients who have died since discharge, or patients where no follow-up was possible.

The table below gives the number of procedures meeting the inclusion criteria, and the percentage of those procedures in which the filter was reported as retrieved (or retrieval was attempted) at any time post-procedure. Because follow-up is critical for assessing filter retrieval, cases meeting the inclusion criteria are broken down into those with follow-up records (at least 1 follow-up record) and those without follow-up records.

<table>
<thead>
<tr>
<th></th>
<th>Your Center</th>
<th>Your Region</th>
<th>VQI Overall</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IVCF procedures meeting inclusion criteria</td>
<td></td>
<td>NA (&lt;3 centers)</td>
<td>1192</td>
</tr>
<tr>
<td>Number without follow-up records</td>
<td></td>
<td></td>
<td>204</td>
</tr>
<tr>
<td>Number with follow-up records</td>
<td></td>
<td></td>
<td>988</td>
</tr>
<tr>
<td>Percentage with Filter Retrieval, or Attempt at Retrieval</td>
<td></td>
<td></td>
<td>56%</td>
</tr>
<tr>
<td>Percentage not retrieved because No Follow-up Records Created</td>
<td></td>
<td></td>
<td>17.1%</td>
</tr>
<tr>
<td>Percentage not retrieved because Not Clinically Indicated</td>
<td></td>
<td></td>
<td>19%</td>
</tr>
<tr>
<td>Percentage not retrieved because Patient Declined</td>
<td></td>
<td></td>
<td>2.3%</td>
</tr>
<tr>
<td>Percentage not retrieved because Lost to Follow-Up</td>
<td></td>
<td></td>
<td>2.2%</td>
</tr>
<tr>
<td>Percentage not retrieved because Deemed Too Late for Removal</td>
<td></td>
<td></td>
<td>0.3%</td>
</tr>
<tr>
<td>Percentage not retrieved because Planned Later Removal</td>
<td></td>
<td></td>
<td>2.2%</td>
</tr>
<tr>
<td>Percentage not retrieved because No Reason Given</td>
<td></td>
<td></td>
<td>1.4%</td>
</tr>
</tbody>
</table>
IVC Filter Retrieval Reporting in Your Region (July 2018–June 2019)

Centers (centers with <10 cases not shown)

*** Indicates center’s rate differs significantly from the regional rate.

IVC Filter Retrieval Reporting by Region Across VQI (July 2018–June 2019)

Regions (regions with <3 centers with at least 10 cases not shown)

*** Indicates region’s rate differs significantly from the VQI rate.
Open Discussion

• Consider unblinding of centers
• Opportunities for enrollment
Regional Improvement Projects

- Mary MacDonald, MD
- Graham Roche-Nagle, MD
National VQI Update:
Betsy Wymer
PSO Quality Director
Number of Participating Centers

Location of VQI Participating Centers

855 VQI Centers
854 centers in North America
1 center in Singapore
18 Regional Quality Groups
Total Procedures Captured (as of 9/1/2021) 862,977

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral Vascular Intervention</td>
<td>289,317</td>
</tr>
<tr>
<td>Carotid Endarterectomy</td>
<td>162,417</td>
</tr>
<tr>
<td>Infra-Inguinal Bypass</td>
<td>69,537</td>
</tr>
<tr>
<td>Endovascular AAA Repair</td>
<td>66,738</td>
</tr>
<tr>
<td>Hemodialysis Access</td>
<td>66,170</td>
</tr>
<tr>
<td>Carotid Artery Stent</td>
<td>61,345</td>
</tr>
<tr>
<td>Varicose Vein</td>
<td>48,389</td>
</tr>
<tr>
<td>Supra-Inguinal Bypass</td>
<td>22,514</td>
</tr>
<tr>
<td>Thoracic and Complex EVAR</td>
<td>22,345</td>
</tr>
<tr>
<td>Lower Extremity Amputations</td>
<td>22,276</td>
</tr>
<tr>
<td>IVC Filter</td>
<td>16,289</td>
</tr>
<tr>
<td>Open AAA Repair</td>
<td>15,393</td>
</tr>
<tr>
<td>Vascular Medicine Consult</td>
<td>198</td>
</tr>
<tr>
<td>Venous Stent</td>
<td>49</td>
</tr>
</tbody>
</table>
VQI wants to help medical students, residents and fellows learn about quality improvement
Trainee engagement

**Purpose:**
To foster understanding of quality process and metrics among Vascular Surgery Residents, Fellow and Medical Students (‘trainees’) through mentorship in the Vascular Quality Initiative (VQI) in collaboration with the Association of Program Directors in Vascular Surgery (APDVS).

**Proposal:**
The SVS/PSO proposes a mentorship program for trainees to learn about surgical quality improvement and research with a focus on vascular disease. Selection of FITs would come from application to the Society for Vascular Surgery (SVS) Patient Safety Organization (PSO) VQI. FITs will be assigned a mentor(s) within one of eighteen VQI Regional Quality Groups as directed by the SVS PSO Governing Council and staff. Any active VQI member meeting requirements can volunteer to serve as a mentor in the program. Regional or Associate Medical Directors are strongly encouraged to take a leadership role in this initiative. The program will eventually be offered to medical students.
Trainee Development Workgroup

- Dr. Gary Lemmon – Chair
- Herb Aronow – SVM
- Dr. Faisal Aziz - PSO Governing Council
- Dr. Mina Boutros – SVS DEI
- Dr. Ashley Gutwein – IU Health 5th Year Resident
- Dr. Beau Hawkins – SCAI
- Dr. Jeff Indes – PSO Governing Council
- Dr. Brigitte Smith - APDVS
- Dr. Gabriella Velazquez - APDVS
- Dr. Ashley Vavra - PSO Governing Council
- Jim Wadzinski – PSO
- Betsy Wymer - PSO
VQI Representatives

- Dr. Leila Mureebe – Chair
- Dr. Carla Moreiro – Vice-Chair
- Dr. Samantha Minc
- Dr. Patricia Fernandez
- Dr. Mina Boutros
- Dr. Rafael Malgor
DEI Committee Inclusion Criteria

• Broad representation
  ➢ Years in practice
  ➢ Region
  ➢ Gender
  ➢ Race
SVS PSO DEI Committee:

**Purpose:**

Recognizing the need for diversity of perspectives to help eliminate bias in the governance and leadership activities of the SVS PSO, the SVS PSO Diversity Committee will work with SVS PSO Councils and Committees to ensure representation of all VQI stakeholders.

**Major Initial Initiative:**

The initial task for the PSO DEI Committee is to develop a baseline understanding of the demographics of the physicians participating in the VQI. The Committee has developed the construct of a survey instrument, which will be launched in September 2021.
The 2021 VQI Annual Meeting was a huge success!

This year, VQI@VAM was a hybrid meeting with all sessions live-streamed. The meeting had approximately 175 attendees participating either remotely or in person throughout the two days.

Thank you to each of our presenters. We appreciate the time and talents you contribute to making this meeting better every year. The information presented was excellent.

Once again, we had amazing poster presentations! Congratulations to Priya Padmanabhan, MHA; Rosha Nodine, BAAS from Baylor Scott & White Health System for winning the ‘VQI member favorite poster’ with their poster “VQI Summary Report Tool in EPIC”.

This year, we added a new poster award called the ‘PSO Director Award’. Congratulations to Donna Fleming, MSN, RN, from Cleveland Clinic for winning this new award with her poster “AAA Size Appropriateness Quality Project”.
**Reminder – If you did a quality presentation using VQI data at any SVS sessions during VAM, you must email bwymer@svspso.org to receive credit for that presentation. Please provide your presentation, as well as your center name. All VQI@VAM presentations have already been given credit.**
We have achieved this remarkable milestone because of your participation and efforts. Thank you for all that you do to make the VQI a success.
Review of primary outcomes in VQI Registry Data since insertion of COVID variables (Sept ’20 through Feb ’21) yielded the following results:

- Overall, > 97% of variable inclusion rate for COVID status in all registries
- Only 1.2% of patients tested positive for COVID-19 → restrictive practices in place and/or patient hesitation/reluctance to seek treatment during pandemic
- Baseline overall mortality across registries of 1.4% rose to 1.6% during time interval while baseline mortality for elective patients who were asymptomatic and COVID (Test negative) remained unchanged
- Patients having a COVID (Test positive) yet Asymptomatic had mortality > twice that of -COVID test patients (OR 2.4)
- Presence of any COVID symptom (aggregate) had mortality of ~4.6 times that of an Asymptomatic and (Test negative) patient (OR 5)
- Mortality of Symptomatic and Intubated patient exceeded 33% across registries
- There was minimal difference in mortality across geographic regions
- Further evaluation will be done on secondary procedure outcomes such as MI, CHF, respiratory failure, graft failure etc.
- LTFU analysis of COVID variable data will require waiting until Sept 2023 for completeness.
The SVS VQI recognizes that traditional outcomes such as patency and reintervention may not fully capture the quality of care or the experience of PAD patients. There is an important need to learn and measure the patient’s perspective.

The My PAD pilot launched April 2021 and includes 20 SVS VQI centers participating in the Peripheral Vascular Intervention Registry. The pilot will test center workflow and seeks to improve PRO collection in the least burdensome manner by leveraging technology, such as smart phones and tablets.
**Highlights**

- Outpatient peripheral vascular interventions (PVI) for claudication or chronic limb threatening ischemia
- Collect VascuQoL-6 and EuroQoL 5D-5L (estimated completion time 10-15 minutes)
- Collection at three time points: pre-procedure, one month and one year postoperatively
- PRO data entry options include paper forms, computer, tablet and smartphone
- Educational materials for direct from patient data entry
- PRO feedback to participating physicians
Regional Meeting CME/CE Credit

Des Moines University is the continuing education provider for this activity.

Each participant **MUST COMPLETE BOTH** the attendance attestation and the meeting evaluation from the URL site – one form.

Approximately 14 days from the meeting, Des Moines University will email you instructions on how to access your certificate.

The attendance roster will be cross-referenced with those applying for CME/CE. Sign in correctly.

You will have 7 days from the date of the meeting to complete the forms and **SUBMIT**.

PSO leadership is providing continuing education credit to you at no charge!

If you do not complete and submit the online forms within 7 days, continuing education credit cannot be awarded.
Meeting Attendance Credit

REMEMBER TO PSO:

• **P**UT your FULL NAME in RingCentral to get credit for attendance and CME/CE credit (no exceptions will be made)

• **S**END an email to ljohnson@svspso.org with names of group members that are sharing 1 device

• **O**FFICIALLY apply for CME/CE credit by clicking this link: https://dmu.co1.qualtrics.com/jfe/form/SV_dbNEd9XfjPKhS4e

You only have **7 days** to complete forms for CME/CE Credit.

NO EMAIL WILL BE SENT AS A REMINDER OR WITH THE CME/CE LINK
Quality Improvement Update

Fall 2021
Welcome to our new SVS PSO Director of Quality!!!

Over the years, Betsy has developed innovative approaches to quality and education for various populations. She has twenty plus years of clinical expertise! As a doctorate prepared nurse, she will apply theory, quality, and research to support the VQI Mission!

Betsy comes to us from ACC/NCDR and we look forward to having her on the VQI team!
Quality Improvement Resources:

- Quarterly Webinars
- Monthly “VQI News”
- QI Project Guide Supplement

The Vascular Quality Initiative | Quality Improvement Tools (vqi.org)
## 2021 Annual Meeting Poster Abstracts

<table>
<thead>
<tr>
<th>Poster/QI PROJECT:</th>
<th>Primary Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAA Size Appropriateness Quality Project</td>
<td>Donna Fleming, RN</td>
</tr>
<tr>
<td>Decreasing Post-Operative Length of Stay after Lower Extremity Bypass</td>
<td>Tracy Campin, RN</td>
</tr>
<tr>
<td>Implementation of an Infection Prevention Bundle for Patients Undergoing Vascular Lower Extremity Bypass Surgical Procedures at Dartmouth-Hitchcock Medical Center: A Quality Improvement Project to Reduce Surgical Site Infections</td>
<td>Mark Abel, MD</td>
</tr>
<tr>
<td>EVAR LTFU at UW Medicine</td>
<td>Amanda Sigala, RN/Nam Tran, MD</td>
</tr>
<tr>
<td>Multi-center implementation of the Clinical Frailty Scale within the vascular surgery clinic workflow for VQI hashtag data collection</td>
<td>Julie Beckstrom, RN</td>
</tr>
<tr>
<td>VQI Summary Report Tool in EPIC</td>
<td>Priya Padmananbhan, RN Rosha Nodine, BAAS</td>
</tr>
<tr>
<td>Leveraging technologies to improve VQI Long term follow up compliance and data documentation: a centralized metadata approach.</td>
<td>Lillian Camino</td>
</tr>
<tr>
<td>Best Practices for Complex Endovascular Procedures</td>
<td>Amanda Sigala,RN/Ben Starnes, MD</td>
</tr>
<tr>
<td>Anticoagulation and Antiplatelet Treatment Plan Communication and Documentation Improvement Project</td>
<td>Aaron Barnes, MD</td>
</tr>
<tr>
<td>Poster/QI PROJECT:</td>
<td>Primary Author</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>Froedtert Hospital Performance Improvement Project to Increase Antiplatelet and Statin Medications Prescribed at Discharge</td>
<td>Juliann Inkmann</td>
</tr>
<tr>
<td>VQI Checklist in the EMR: Impact on Statin and Antiplatelet Prescriptions at Discharge</td>
<td>Claire Motyl, BA</td>
</tr>
<tr>
<td>Using VQI and EMR chart alerts to increase compliance of statin and aspirin, a retrospective study</td>
<td>Jennifer Landis PA-C</td>
</tr>
<tr>
<td>Development of a Successful Process to Enhance the Transition between Data Managers</td>
<td>Donna Albergo, RN</td>
</tr>
<tr>
<td>Road to Recovery for Patients Undergoing Vascular Procedures at the Heart and Vascular Center</td>
<td>Sandy Fillion, MSN</td>
</tr>
<tr>
<td>Sustaining High Performance in Long Term Follow Up Care</td>
<td>Rouchelyn Fallorina, RN</td>
</tr>
<tr>
<td>Increasing data entry rates for VQI variables using SmartText: a pilot approach</td>
<td>Aravind Ponukumati</td>
</tr>
<tr>
<td>Implementation of a Long Term Follow Performance Improvement Project for the TEVAR and Complex EVAR Module</td>
<td>Zdenek Novak</td>
</tr>
<tr>
<td>Implementation of providing patients with surgical site care instructions and supply kits on day of discharge to decrease surgical site infections</td>
<td>Sue Nappo, RN</td>
</tr>
<tr>
<td>Impact of preoperative anemia in patients undergoing peripheral vascular intervention</td>
<td>Abdul Kader Natour, MD</td>
</tr>
</tbody>
</table>
Charter participants become part of focused group calls
- Interactive discussion sharing barriers and successes
- Sharing of charters
- Networking
- Checking in – where are you in the process
- Celebrating success

One on one calls, if requested
National QI project details

• Submit Project Charters and supporting documentation for presentations and posters to QI@SVSPSO.ORG or Bwymer@svspso.org

• Visit the VQI Members Only Website for sample charters, webinars, and presentations on VQI Quality Improvement Projects. www.vqi.org
Participation Awards
Participation Awards Program

- Participation Awards began in 2016 to encourage active participation in the registries program and recognize the importance of participation.

- Participating centers can earn up to three stars based on actions that lead to better patient care – more details available at https://www.vqi.org/quality-improvement/participation-awards/
MAJOR CHANGE

- Long Term Follow-Up 2018 cases
  - COVID-19 affect
  - Remove LFTU from the 2020 Participation Award – BUT...
  - Acknowledge centers that maintained, improved LTFU with a certificate
    - Centers in top 25% for 2018 LTFU rates
    - Statistically significant increase in LTFU rate from 2017 to 2018
Scoring 2020 (During COVID-19)

• Three categories scored, each on a 0-6 point scale:
  o LTFU – REMOVED. Separate recognition.
  o Meeting attendance (weighted 50%)
  o QI project involvement (weighted 40%)
  o Number of registry subscriptions (weighted 10%)

• The final score is calculated as follows:
  Total points = 5 x Attendance score + 4 x QIP score + 1 x Registry score
Effective immediately the Participation Committee unanimously voted to re-instate LTFU criteria in the 2021 Participation Awards.

The following is a list of the four domains for the 2021 Participation Awards criteria:

Domain 1 – LTFU – 40% weighted
Domain 2 – Regional Meeting attendance – 30% weighted
Domain 3 – QI Project – 20% weighted
Domain 4 – Registry subscriptions – 10% weighted

The final score is calculated as follows:
Total points = 4 x LTFU score + 3 x Attendance score + 2 x QI score + 1 x registry score
Arterial Quality Council:
Mary MacDonald, MD
AQC Update:

- **Development Priorities for end of 2021/ early 2022**
  - Infra/Supra revisions goal to complete by end of 2021
  - OAAA revision goal to complete by end of Q2 2022

- **New “Pathways” follow up reports**
  - CAS, EVAR available
  - CEA, TEVAR, PVI, HDA available late 2021 - early 2022
  - All other registries to follow
AQC Update:

• Clinical Appropriateness Performance Indicators (CAPI reports)
  o Aligning with SVS Guidelines

• Standard Operative Notes
  o We have resumed talks with Epic and have restarted the initiative to create standard op notes, which will enable automated data abstract, based on the standardized notes. This functionality would be available to all Epic users.

• Registry Specific Quality Improvement Initiatives

• Patient Reported Outcomes: My PAD PRO Pilot PVI

• Opioid variables: Infra-Inguinal – Available August

• Registry Education: recorded sessions!!
  – All available on VQI.org  https://www.vqi.org/resources/webinars-events/
The Society for Vascular Surgery Patient Safety Organization® (SVS PSO) and the Society for Vascular Medicine (SVM), in collaboration with the American Heart Association® (AHA), are excited to introduce the SVS Vascular Quality Initiative’s Vascular Medicine Consult (VMC) Registry.

This Registry will target the management of NEW Outpatient Consults who are being treated medically for:

- Atherosclerotic carotid artery occlusive disease
- Abdominal Aortic aneurysm
- Peripheral lower extremity arterial disease due to atherosclerosis or true aneurysm

The Vascular Medicine Consult Registry provides a unique opportunity to look at the natural history of a disease and what factors impact the progression. The emphasis of this Registry will be medication details and dosages, risk factor and lifestyle modifications such as exercise and diet, and non-operative treatments and counseling. The value of this Registry centers on the comparative effectiveness of surgery vs. medically managing these vascular diseases.

Learn more: [The Vascular Quality Initiative | Vascular Medicine Consult Registry (New) (vqi.org)]
Venous Quality Council:
Graham Roche-Nagle, MD
Venous SVS PSO Organization

SVS PSO Venous Arm

**Governing Council**
- 4 SVS Representatives
- 2 AVF Representatives
- 18 Regional Group Representatives

**Research Advisory Council (Venous RAC)**
- Chair: Nicholas Osborne

**Venous Quality Council (VQC)**
- Chair: Marc Passman
- 3 AVF + 2 SVS Representatives
- 18 Regional Group Representatives

**IVC Filter Committee**
- Chair: Tony Gasparis

**Varicose Vein Committee**
- Chair: Nick Osborne

**Venous Stent Committee**
- Chair: William Marston
Three Year Goals for VQC:

- Dedicated podium time for VQI at AVF
- Update Varicose Vein and IVC quarterly interoperative dashboards
- Create Venous Stent dashboard
- Work on LTFU dashboards for all 3 venous procedures
- Continue work C2 disease and appropriateness of care
- Continue work with United Healthcare
- Create COPI (Center Opportunity for Process Improvement) reports
- Create CAPI (Clinical Appropriateness Performance Indicators) reports
Inclusion Criteria:
Percutaneous (closed) and/or cut-down (open) procedures to treat patients with symptomatic venous obstructions due to chronic thrombosis and/or some venous compression disorders. Vessels included: Inferior Vena Cava, Common iliac vein, External iliac vein, Common Femoral Vein, Deep Femoral Vein, Femoral Vein, Popliteal Vein.

- Acute obstruction of the Vein;
- Chronic thrombotic obstruction = Chronic Stenosis/Obstruction of the Vein;
- Non-thrombotic stenosis/compression such as May Thurner (iliac vein compression syndrome)

Exclusion Criteria:
- Venous Stent of the Internal Iliac (hypogastric), Great Saphenous Vein, Superior vena cava, Renal Veins, Subclavian vein, Jugular vein, Innominate vein and any upper extremity veins
- Vein Diameters that are not treatable per stent sizing recommendations
- Venous Inflow or Outflow issues precluding stent placement
Arterial Research Advisory Council:
Graham Roche-Nagle, MD
New RAC Education!!

Dr. Leila Mureebe,
SVS PSO Associate Medical Director

– Creating videos on how to submit a RAC Proposal for “success”
– Creating useful tools and tips to train new investigators
1. Review list of projects:
https://www.vqi.org/data-analysis/rac-approved-project-search/

2. Submit proposal online:
http://abstracts123.com/svs1/meetinglogin

3. Deadlines for submissions:
The Vascular Quality Initiative | National Arterial and Venous RAC Schedules (vqi.org)
VISION: Vascular Implant Surveillance and Interventional Outcomes Network.

- It is a partnership between the Society for Vascular Surgery Patient Safety Organization’s Vascular Quality Initiative (SVS PSO) and Medical Device Epidemiology Network (MDEpiNet). The goal is to improve the quality, safety and effectiveness of vascular care.

- VISION developed algorithms, which allows certain VQI registry patients to be matched to Medicare claims data. Claims linkage allows very complete follow up on CMS patients (greater than 65 years of age, dialysis, etc).

- VISION’s primary goal is to facilitate low-cost, high-value and real-world evidence research through the creation of a national repository of linked clinical-claims analytic data sets. The secondary objectives are to measure the safety and effectiveness of vascular devices.
VISION: SRS Reports!

• The Vascular Quality Initiative is pleased to provide participating members with center-specific Survival, Reintervention, and Surveillance Reports (SRS).

• SRS reports are produced by the VQI as part of the Vascular Implant Surveillance and Interventional Outcomes Network (VISION) Project, a partnership between the VQI and the Medical Device Epidemiology Network (MDEpiNet). The reports are based on VQI-Medicare linked data. Each report shows each center’s long-term performance when compared to the VQI for Medicare patients undergoing the following procedures:
  ▪ endovascular abdominal aortic aneurysm repairs (EVAR)
  ▪ elective abdominal aortic aneurysm repair (EVAR + Open AAA)
  ▪ carotid endarterectomy for asymptomatic stenosis
  ▪ carotid artery stent procedures (TCAR and transfemoral procedures) for asymptomatic stenosis

• FAQs on the methods and definitions used to generate these reports can be found on the VQI Website (VQI.org). The goal of the SRS reports is to help VQI members assess their performance on these important metrics compared to the rest of the VQI and to improve the quality of vascular care at their center.
GC Update: Graham Roche-Nagle, MD

• April 2021 meeting updates:
  – COVID collaboration with VASCC
  – Improved reporting (PSO reports/MedStreaming)
  – US News and World Report Collaboration
  – Data Integration (EPIC/Cerner)
  – Relationships (Societies/FDA/CMS/Industry)
  – SVS PSO Diversity Committee
Follow up from Spring meeting

- Paper to be published in JVS regarding Aortic Sx and ERAS
- ERAS@VQI committee – Dr. Kate McGinigle
- Podcast: ‘Audible Bleeding’
  https://podcasts.apple.com/ca/podcast/audible-bleeding/id1440614377?i=1000524288713
Rotating Chair: Graham Roche-Nagle, MD

- Rotating Chair for Meetings based on length of time in CVQI:
  - Spring 2022  Mary McDonald
  - Fall 2022    Stephanie Elkouri
  - Spring 2023  Patrice Nault
  - Fall 2023    Pat Casey
  - Spring 2024  Paul Petrasek
Case Presentations
VQI Quality Initiatives at NS Health

• **Discharge Medication:** Education Sessions with nurses on vascular unit. Focused on importance of both antiplatelet and statin being prescribed at discharge unless contraindicated.

• **Documentation and LTFU:**
  • Flagging vascular patients on STAR (patient processing system) used for admissions/transfer/discharges.
  
  • Aim: To notify health care providers that patient is a part of VQI, prompting documentation points required for registries.

  • Aim: Create weekly report notifying data abstractor of flagged patients who have had follow up appt.
Thresholds for abdominal aortic aneurysm repair in Canada and United States

Ben Li MD, Philippe Rizkallah MD, Naomi Eisenberg PT MEd CCRP,
Thomas L. Forbes MD, Graham Roche-Nagle MD MBA

Divisions of Vascular Surgery, Peter Munk Cardiac Centre, University Health Network,
University of Toronto
Objective

• To assess differences in patient selection, operative technique, and outcomes for abdominal aortic aneurysm (AAA) repair in Canada vs. United States

Methods

• The Vascular Quality Initiative (VQI) was used to identify all patient who underwent elective endovascular or open AAA repair between 2010-2019 in Canada and United States
Main finding

• Analysis of 51,455 US patients and 1,451 Canadian patients in the VQI database demonstrated that US patients were more likely to receive AAA repair below recommended thresholds of 5.5 cm for men and 5.0 cm for women compared to Canadian patients (38.8% vs. 15.2%, OR 3.57 [95% CI 3.03 – 4.17], p < 0.001).

Conclusion

• Quality improvement projects are needed to standardize AAA management
Other U of T Projects

- Sex differences in Outcomes of CEA
- Sex differences in Outcomes of oAAA
- Review of effect of KatKatsanos et al’s article (Accepted to JVS)
- SUPERA stenting in the common femoral artery: Early Experience and Practical Considerations (submitted to Vascular and Endovascular Surgery)
- Hemoglobin thresholds and predictors of outcomes (ongoing)
Sex differences in outcomes following ruptured abdominal aortic aneurysm repair

Ben Li MD, Naomi Eisenberg PT MEd CCRP, Miranda Witheford MD PhD, Thomas F. Lindsay MD MSc, Thomas L. Forbes MD, Graham Roche-Nagle MD MBA

Divisions of Vascular Surgery, Peter Munk Cardiac Centre, University Health Network, University of Toronto
Objective

• To assess differences in ruptured abdominal aortic aneurysm (rAAA) repair outcomes between women and men

Methods

• The Vascular Quality Initiative (VQI) was used to identify all patient who underwent endovascular or open rAAA repair between 2003-2019
Main findings

• Analysis of 1,160 women and 4,148 men who underwent rAAA repair at VQI sites demonstrated that survival up to 8 years was lower in women (36.7% vs. 49.5%, HR 1.25 [95% CI 1.04 – 1.50], p = 0.02)
• Women were older and more likely to have chronic kidney disease, which were important predictors of mortality

Conclusion

• There are significant sex disparities in rAAA repair outcomes and opportunities exist to improve care for women
Effect of Vertebral Compression Fractures On Aortic Neck Angulation After Endovascular Aneurysm Repair

Omid Shearkhani¹, Taryn J. Rohringer², Naomi Eisenberg³, Sebastian Mafeld¹, Kong T. Tan¹, Arash Jaberi¹, Graham Roche-Nagle¹,³

¹Joint Department of Medical Imaging, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada
²Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
³Department of Vascular Surgery, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada
HIGHLIGHTS

- **Type of Research:** Single-center retrospective cohort study.
- **Key Findings:**
  - Patient data from August 2010 to December 2018 were extracted from the Society for Vascular Surgery Vascular Quality Initiative (VQI) database, along with our institution’s PACS and electronic health records software (EHR).
  - During follow-up period, 10 out of 185 post-EVAR patients had a radiologically significant vertebral body compression fracture.
  - Patients with compression fractures (Study group) were matched to a Control group, using propensity-score matching, to account for known factors affecting aortic geometry, namely gender, age, and time.
  - Moreover, the Study and Control groups were shown to have similar pre-operative aortic neck morphology indices (including neck length, minimum diameter, percent thrombus, and largest aneurysm sac size diameter), along with pre-operative and early post-operative ANA which are factors that affect changes in ANA post-EVAR.
  - Results showed there to be a statistically significant exacerbation of ANA on follow-up scans in patients with compression fractures (Δ = 7.2° vs. -4.7°; p-value = 0.009; power = 0.838).
HIGHLIGHTS

- Take home Message:
  - Post-EVAR vertebral body compression fractures exacerbates aortic neck angulation.
  - Given aortic neck angulation is an important predictor of post-operative complications, awareness of this association can guide both pre-operative assessment and post-operative management and follow-up.
Endovascular community response to mortality data in use of paclitaxel devices for peripheral vascular disease

BLAIR EDWARD WARREN, M.D, BSC, GRAHAM ROCHE-NAGLE, M.D, MBA, JASON ZHU, BSC, GUAN WANG, BSC, NAOMI EISENBERG, PT, MED, CCCRPB, DHEERAJ K. RAJAN, M.D, SEBASTIAN MAFELD, MBBS.
Introduction and Objective

- Following the Katsanos et al. meta-analysis in 2018, the safety of paclitaxel devices for peripheral arterial disease was brought into question.
- The change in use of these devices had not been documented.
- It was expected that given the mortality concern, there would be a reduction in overall paclitaxel device use.
- Additionally, it was expected that paclitaxel devices would continue to be used in patients who are more unwell / comorbid.

Objective: Examine the endovascular community response to mortality data in paclitaxel devices in peripheral arterial disease.
Methods

- Using the Vascular Quality Initiative’s Peripheral Vascular Intervention dataset, count data for use of both paclitaxel (stents and drug eluting balloons) and non-drug coated devices were obtained.

- Patients were labelled according to primary symptoms claudicant (mild, moderate, or severe) and critical limb ischemia (ischemic rest pain or ulcer/necrosis).

- Statistical analysis was performed to examine for reduction in overall use as well as subgroup analysis.
Results / Conclusions

- Significant reduction in paclitaxel stent and balloon use was observed in 2019 following the publication of the Katsanos et al. meta-analysis.
  - Paclitaxel device use dropped from 50.6% in 2018 to 31.6% in 2019.
- There was concordant increase in plain balloon and non-paclitaxel stent use.
- Limited conclusions can be drawn regarding patient selection, as there was significant fluctuation in paclitaxel device use throughout 2019.
Meeting Attendance Credit

REMEMBER TO PSO:

• **P**UT your FULL NAME in RingCentral to get credit for attendance and CME/CE credit (no exceptions will be made)

• **S**END an email to ljohson@svspso.org with names of group members that are sharing 1 device

• **O**FFICIALLY apply for CME/CE credit by clicking this link: https://dmu.co1.qualtrics.com/jfe/form/SV_dbNEd9XfjPKhS4e

You only have **7 days** to complete forms for CME/CE Credit.
NO EMAIL WILL BE SENT AS A REMINDER OR WITH THE CME/CE LINK
Medstreaming + M2S are now Fivos

About Our Name
Fivos is an alternate name for the ancient Greek deity, Apollo: God of light, truth, medicine and healing. Celebrates our roots in imaging, our focus on healing, and our commitment to defragmenting insights across healthcare.

Visit: https://fivoshealth.com/ for more information
Medstreaming + M2S are now Fivos

About Our Name
Fivos is an alternate name for the ancient Greek deity, Apollo: God of light, truth, medicine and healing. Celebrates our roots in imaging, our focus on healing, and our commitment to defragmenting insights across healthcare.

Visit: https://fivoshealth.com/ for more information
Updates for 2021 Fall
VQI Regional Meeting
Technology Updates for VQI
Released in Q1 2021

“Release Notes” in the PATHWAYS Support tab

- Released on 1/13/2021
- This feature will allow PATHWAYS users to search for and review release notes and announcements that have been released after 1/13/2021. The new “Release Notes” button will be located on the “Support” tab, in the upper left corner.
- Release Notes will be presented in an interactive report so users may search or filter the report as needed.
- The last column in the report will display a “View” icon. Click on the icon to view the release document.
- Release announcements will continue to be sent via email and will then also be posted here for historical reference with the most recent notes listed first by default.
Record Information feature

- Released on **1/13/2021**
- A new feature was introduced to the procedure and follow-up pages in PATHWAYS that provides access to record information for each form created. Upon opening a procedure/treatment or follow-up form, “Record Information” will be accessed by clicking on a new info icon which will appear with the “Patient Information” listed at the top of Procedure/treatment records and in the “Note” section above the “Existing Information” section of Follow-up records. Record Information will be available for all PATHWAYS procedure and follow-up records with the exception of the Thoracic and Complex EVAR registry, which will be updated in the future to include this new feature.
- Clicking the info icon will open a pop-up to display the following details:
Released in Q1 2021
Enhancements to Users and Permissions report

- Released on **1/13/2021**
- PATHWAYS Hospital Managers who manage users at multiple centers within a health system are now able to view all users across all of the centers they have access to in their “Users and Permissions Report.” It doesn’t matter which of those centers they are currently logged into on PATHWAYS when they generate the report. This saves time by allowing easy comparison of permissions for different users and centers.
- The Users’ Status filter now includes the options of All Users, Active Users, or Inactive Users to provide filtering by user status.
- A new “2 Factor Authentication” column was added to the report. The values in the “2 Factor Authentication” (2FA) column will be “Enabled” or “Disabled” based on whether the user account has enabled 2FA for security. There is an associated “PATHWAYS 2 Factor Authentication” guide on the “Resources” tab for more information about this security feature.
- A new report description now displays at the top of the “Users and Permissions Report”:
  - The Users and Permissions Report displays user accounts and permissions associated with Centers you manage. The report will allow you to view account details, privileges, analytics and report access details.
  - Utilizing the options for User’s Status allows you to filter the report by "all, active only, or inactive only" user accounts.
Released in Q1 2021

Move Records feature

- Released on 2/3/2021
- New functionality to move existing procedure records from one patient record to another was introduced, along with a new “Move Records” privilege in the Data Management Tools section. This will help in cases where duplicate patients are created and the records need to be consolidated to a single patient record, or a procedure was entered under the wrong patient and needs to be moved to the correct patient.
- On the “Data Management” tab, under “Patient Details”, the patient’s procedure record summary, will include a new column of checkboxes at the end of each procedure record row.
Move Records feature

- Released on 2/3/2021
- New functionality to move existing procedure records from one patient record to another was introduced, along with a new “Move Records” privilege in the Data Management Tools section. This will help in cases where duplicate patients are created and the records need to be consolidated to a single patient record, or a procedure was entered under the wrong patient and needs to be moved to the correct patient.
- On the “Data Management” tab, under “Patient Details”, the patient’s procedure record summary, will include a new column of checkboxes at the end of each procedure record row.
- A confirmation window will open which compares the patient details between the current patient record and the new patient record selected for verification before completing the move.
Released in Q1 2021

“Insights” Follow-up Outcomes Report for EVAR

- Released on 2/3/2021
- A new “Follow-up Outcomes Report,” developed by the SVS PSO, is presented in a separate tab labeled “Insights” in PATHWAYS. The report provides key follow up metrics for VQI® sites with center data as well as regional and all VQI benchmarking. The report will be available initially only for the Endovascular AAA Repair (EVAR) registry. We will provide similar reports for other registries in the future.
- The report has drill down capabilities to better understand the data entered by the site at the procedure level.
- Permission to access the EVAR Follow-up report was enabled for all existing EVAR Hospital Managers at the time of release. Hospital Managers may grant access to others by updating the report permissions on the 2nd page of their user accounts (where the Analytics permissions are also managed).
- A new column for “Insights” permissions is available in the “Users and Permissions Report” tool in PATHWAYS.
Released in Q1 2021

“Share a File” enhancements

• Released on 2/3/2021

• We converted the “Share a File” tables, “My Shared File(s)” and “File(s) Shared with Me”, to PATHWAYS interactive reports. This enhancement provides added capabilities to sort, filter, and search for shared files.

• Users can click on the “Actions” button and select “Help” for more information about these and other interactive reporting functions.

• Additionally, we converted the former “delete” icon on each row to a checkbox, so that multiple files can be selected and deleted at once. There is no change to the process for sharing files or the files that have been shared. Note: not all users have shared files.
HDA Analytics update

- Released on **3/10/2021**

- We introduced a new reporting variable in the Analytics & Reporting Engine that aggregates the Side of Access variables collected on the HDA History tab. It can be used for reporting as a variable, filtering, and creating User Calculated Variables (UCVs). The new “Side of Access” variable options include:
  - Right = Side of Access is Right for all previous access sites recorded.
  - Left = Side of Access is Left for all previous access sites recorded.
  - Bilateral = Side of Access is one of Left or Right for previous access sites recorded.
  - Missing Value or N/A = Side of Access is missing for any previous access site recorded.
Released in Q2 2021

“Recent Records” list

• Released on 4/14/2021

• The new Recent Records list appears on the Enter a New Patient or Find an Existing Patient details page (see example image below). The Recent Records list provides quick and easy access to a list of the last 50 records the user edited.

• The “Recent Records” list default setting is displayed in groups of 10 and is sorted in descending date by the “My Last Updated Date” column.

• Users may quickly access any of the patient records in the Recent Records list by clicking on either the Record ID, Procedure Date, or Patient Last Name.
Released in Q2 2021

Reporting tab

- Released on **6/15/2021**
- In preparation for future reporting enhancements, PATHWAYS will include a new "Reporting" tab located in the top-right with the existing tab options.

- The Analytics & Reporting Engine may be accessed from the new Reporting tab or via the existing Analytics & Reporting Engine link on the Data Management tab. In either case, the current Analytics & Reporting Engine tool will be presented from within the Reporting tab along with new reports that become available in the future.
Reporting tab, cont.

- The Reporting tab will include the following features:
  - The "Home" button in the top left corner returns to the "Patient Search" page.
  - The left side panel will host a menu of navigational tools and available reports and includes the link to the Analytics & Reporting Engine.
  - Users can log out from PATHWAYS on this page by selecting the log out function from the drop down menu accessed by clicking the username in the upper right corner.

Released in Q2 2021
Projects in Progress

Coming soon

• Minor revision to CEA, CAS, and VMC to add stenosis and contralateral events
• Add Opioid variables to INFRA
• Follow-up Outcomes reports for CAS, CEA and EVAR using new reporting technology
• New Device Assistant feature to streamline device search and selection
• Minor revision to TEVAR to update dependencies for Entry Flow and Dissection Date/Type
• Minor revision across registries to change Gender to Sex, add COVID Vaccination variables, and add medical resident variables
• Minor revision to IVC Filter manufacturer options
Projects in Progress

What’s next?

- Major revision to INFRA and SUPRA registries
- Major revision to Open AAA registry
- Enhancements to data download functionality
Registry Projects
SVS Post-Market Surveillance Projects

• These projects are conducted within the SVS PSO and only non-identifiable data (removal of patient, center and physician information) will be provided to Medtronic/BARD/Cook/Gore or the FDA. Only standard of care practice is being evaluated. For such PSO activities, patient informed consent and Institutional Review Board review are not required.

• Sites must follow their institutional guidelines.
The SVS PSO is excited to announce the continuation of the TEVAR Dissection Surveillance Project to evaluate the Cook Zenith Dissection Endovascular System. FDA approval was granted for this device after safety and effectiveness were demonstrated in pre-market studies of complicated dissection with the proviso that the efficacy of TEVAR treatment of descending aortic dissection would be more fully analyzed through post-market surveillance, as was done through VQI for the W. L. Gore and Medtronic devices after their approval.

- Patients will have 30 day, and annual visits for 5 years.
- Total reimbursement of $4,000 per patient for a patient followed annually for 5 years.
TEVAR Dissection Surveillance Project
Open for Enrollment

• 40 of the 180 required patients enrolled (13 potential cases in process)
  • Retrospective enrollment allowed- All eligible cases from December 31, 2018 (protocol FDA approval date)
  • 14 30-Day visits completed, 4 1-year follow-up visits completed
• 30 of 40 sites enrolled (8 more in contracting)
  • This project is conducted within the SVS PSO and only non-identifiable data (removal of patient, center and physician information) will be provided to Cook or the FDA. Only standard of care practice is being evaluated. For such PSO activities, patient informed consent and Institutional Review Board review are not required.

For more information, please contact: tevarproject@fivoshealth.com
TEVAR Dissection Surveillance Project
5 Year Project Gore and Metronic Arm

• Initiated in October 2014, the TEVAR Dissection Surveillance Project Arm evaluates the W.L. Gore and Medtronic devices for treatment of Type B thoracic dissections.

• Meeting FDA requirement
  • 194 chronic and 200 acute patients with device technical success

• Currently in 5-year follow-up phase
PATHWAYS Support

Claims Validation

The annual claims validation process is intended to ensure that all eligible cases have been captured in the registry and is a requirement of participation in the VQI.

The 2019 Claims Validation process was launched in July 2020.

- Almost 70% of selected centers have completed validation or are in progress.
- The deadline to finish is 10/31/21.
- PATHWAYS Support is here to help you. Please reach out if your center was selected to participate in the audit and would like assistance.

The launch of 2020 Claims Validation is coming soon. Stay tuned!
What’s New?

Please check out recent enhancements designed to improve your PATHWAYS experience. Let us know what you think!

- Move Record – Move procedure data to the correct patient when duplicate/miskeyed patient records have been identified.
- Audit Info – View record details including creator and created date, last user to update and date updated, and form validation submission status.
- Recent Records – Quickly return to your recently accessed procedure and follow up records.
- Release Notes - Go to the Support Tab to access historical release announcements to review recent updates.
- Reporting Tab – This new tab will be home to future new data analysis reporting including the current analytics engine.
PATHWAYS Support

Coming Soon...

The Support Team will be implementing training opportunities for new and existing PATHWAYS users to learn about PATHWAYS functionality.

More details to come!
Final Thoughts

• Consider location for Spring 2022 meeting in conjunction with National Meeting

• In-Person v Hybrid v Remote
Thank You